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Proteomics is the large-scale study of the structure and function of proteins in complex biological sample. Such an approach
has the potential value to understand the complex nature of the organism. Current proteomic tools allow large-scale, high-
throughput analyses for the detection, identiﬁcation, and functional investigation of proteome. Advances in protein fractionation
and labeling techniques have improved protein identiﬁcation to include the least abundant proteins. In addition, proteomics
has been complemented by the analysis of posttranslational modiﬁcations and techniques for the quantitative comparison of
diﬀerent proteomes. However, the major limitation of proteomic investigations remains the complexity of biological structures
and physiological processes, rendering the path of exploration paved with various diﬃculties and pitfalls. The quantity of data
that is acquired with new techniques places new challenges on data processing and analysis. This article provides a brief overview
of currently available proteomic techniques and their applications, followed by detailed description of advantages and technical
challenges. Some solutions to circumvent technical diﬃculties are proposed.
Copyright © 2009 K. Chandramouli and P.-Y. Qian. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
The term proteomics describes the study and characteriza-
tion of complete set of proteins present in a cell, organ,
or organism at a given time [1]. In general, proteomic
approaches can be used (a) for proteome proﬁling, (b)
for comparative expression analysis of two or more pro-
tein samples, (c) for the localization and identiﬁcation of
posttranslational modiﬁcations, and (d) for the study of
protein–protein interactions. The human genome harbors
26000–31000 protein encoding genes [2]; whereas the total
numberofhumanproteinproducts,includingsplicevariants
and essential posttranslational modiﬁcations (PTMs), has
been estimated to be close to one million [3, 4]. It is
evident that most of the functional information on the
genes resides in the proteome, which is the sum of multiple
dynamic processes that include protein phosphorylation,
protein traﬃcking, localization, and protein-protein inter-
actions [5]. Moreover, the proteomes of mammalian cells,
tissues, and body ﬂuids are complex and display a wide
dynamicrangeofproteinsconcentrationonecellcancontain
between one and more than 100000 copies of a single
protein [6]. In spite of new technologies, analysis of complex
biological mixtures, ability to quantify separated protein
species, suﬃcient sensitivity for proteins of low abundance,
quantiﬁcation over a wide dynamic range, ability to analyze
protein complexes, and high throughput applications is
not yet fulﬁlled [7]. Biomarker discovery remains a very
challenging task due to the complexity of the samples
(e.g., serum, other bodily ﬂuids, or tissues) and the wide
dynamic range of protein concentrations [8]. Most of the
serum biomarker studies performed to date seem to have
converged on a set of proteins that are repeatedly identiﬁed
in many studies and that represent only a small fraction of
the entire blood proteome [9]. Processing and analysis of
proteomics data is indeed a very complex multistep process
[10, 11]. The consistent and transparent analysis of LC/MS
and LC-MS/MS data requires multiple stages [12], and this
process remains the main bottleneck for many larger pro-
teomics studies. To overcome these issues, eﬀective sample
preparation (to reduce complexity and to enrich for lower
abundance components while depleting the most abundant2 Human Genomics and Proteomics
ones), state-of-the-art mass spectrometry instrumentation,
and extensive data processing and data analysis are required.
A wide range of proteomic approaches are available such
as gel-based applications include one-dimensional and two-
dimensional polyacrylamide gel electrophoresis [13,14],and
gel-free high throughput screening technologies are equally
available, including multidimensional protein identiﬁcation
technology[15],isotope-codedaﬃnitytagICAT[16];SILAC
[17]; isobaric tagging for relative and absolute quantitation
(iTRAQ) [18]. Shotgun proteomics [19]a n d2 D ED I G E
[20]a sw e l la sp r o t e i nm i c r o a r r a y s[ 21, 22] are applied
to obtain overviews of protein expression in tissues, cells,
and organelles. Large-scale western blot assays [23], multiple
reaction monitoring assay (MRM) [24], and label-free
quantiﬁcation of high mass resolution LC-MS data [25]a r e
being explored for high throughput analysis. Many diﬀerent
bioinformatics tools have been developed to aid research in
this ﬁeld such as optimizing the storage and accessibility of
proteomic data or statistically ascertaining the signiﬁcance
of protein identiﬁcations made from a single peptide match
[26]. In this review we attempt to provide a overview of the
major developments in the ﬁeld of proteomics, some success
stories as well as challenges that are currently being faced.
2. GeneralLimitations of
the Proteomic Analysis
2.1. Membrane Proteome. About 20–30% of all genes in
an organism encode integral membrane proteins, which
are involved in numerous cellular processes [27]. Mem-
brane proteins constitute 30% of the typical proteome,
yet their propensity to aggregate and precipitate in solu-
tion confounds their analysis [28]. The target residues
for tryptic cleavage (i.e., lysine and arginine) are mainly
absent in transmembrane helices and preferentially found
in the hydrophilic part of these lipid bilayer-incorporated
proteins. Because of the protein aggregation step of IEF,
2DE is unsuitable for the separation of integral mem-
brane proteins and is limited to detection of membrane-
associated proteins and membrane proteins with a low
hydrophobicity[29].Membranesolubilizationmethodshave
been deployed to analyze enriched membrane fractions
and address the solubility issue by using detergents [30],
organic solvents [31], and organic acids [32]c o m p a t i b l e
with subsequent proteolytic digestion/chemical cleavage,
separation and analysis by LC/MS. In this approach, (1)
an enriched yeast membrane fraction is solubilized with
90% formic acid in the presence of cyanogens bromide. The
concentrated organic acid provides the solubilization agent,
and cyanogen bromide, functional under acidic conditions,
allows many embedded membrane proteins to be cleaved,
(2) a membrane-enriched microsomal fraction is solubilized
by boiling in 0.5% SDS and, following isotope-coded aﬃnity
tag (ICAT) labeling, is diluted to reduce the concentration
of SDS, and (3) by using an enriched membrane sample,
the proteins are thermally denatured and sonicated in 60%
organic solvent (methanol) in the presence of trypsin.
The resultant peptide mixture is then analyzed by LC/MS.
All three of these methods are eﬀective and optimize the
identiﬁcationsofmembraneproteins.Anothermethodusing
high pH and protenase K is optimized speciﬁcally for the
global analysis of both membrane and soluble proteins [33].
High pH favors the formation of membrane sheets, while
proteinase K cleaves exposed hydrophilic domains of mem-
brane proteins. Commercially available nonionic detergents,
dodecyl maltoside, and decaethylene glycol mono hexadecyl
are proved most eﬃcient membrane protein solubilizers
[34].Anothermoresuccessfulapproachtoisolatemembrane
proteins relies on cell surface labeling in combination with
high resolution two-dimensional (2D) LC-MS/MS [35]. In
addition,improvedanalyticaltoolsshouldbedeveloped,that
is, multidimensional liquid chromatography of peptide mix-
tures generated from membrane proteins, nanoﬂow chro-
matographic techniques for hydrophobic transmembrane
peptides, and native electrophoresis of membrane protein
complexes, which, in combination with mass spectrometry,
should lead to the identiﬁcation of the majority of proteins
in the membrane proteome of simple microorganisms. It
is important to quantify not only the identiﬁed membrane
proteins but also to determine the levels of interacting
partners. Subcellular fractionation techniques that employ
a combination of centrifugation steps are a common
choice for preparing plasma membrane-(PM-) enriched
fractions including detergent-resistant membrane fractions,
commonly known as lipid rafts. These methods can oﬀer a
signiﬁcant improvement in speciﬁcity for PM proteins over
approaches that do not perform any subcellular fractiona-
tion, but rather use whole-cell or tissue preparations [36].
Chemical-tagging methods [37] have been a more applied
technique used to enrich for PM proteins and are often
used in conjunction with physical separation strategies. This
method allows for a speciﬁc class of protein or modiﬁcation
of interest to be physically separated from other nontagged
proteins. Importantly, when chemical tags are attached to
the extracellular domain of PM proteins on intact cells,
they oﬀer an unrivaled speciﬁcity for PM proteins, because
they oﬀer a manner to distinguish true PM proteins from
intracellular contaminants. Cell-surface biotinylation, the
covalent attachment of a biotin tag to the extracellular
domain of PM proteins, is also a popular choice [38–40].
2.2. Serum Proteomics and Biomarker Discovery. Serum is a
complex body ﬂuid, containing a large diversity of proteins.
More than 10000 diﬀerent proteins are present in the human
serum and many of them are secreted or shed by cells during
diﬀerent physiology or pathology processes [41]. Serum is
expected to be an excellent source of protein biomarkers
because it circulates through, or comes in contact all tissues.
Consequently, serum proteomics has raised great expecta-
tions for the discovery of biomarkers to improve diagnosis
or classiﬁcation of a wide range of diseases, including
cancers [42]. However, serum has been termed as the most
complexhumanproteome[43]withconsiderablediﬀerences
in the concentrations of individual proteins, ranging from
several milligrams to less than one pictogram per milliliter
[44]. The analytical challenge for biomarker discovery arises
from the high variability in the concentration and state
of modiﬁcation of some human plasma proteins betweenHuman Genomics and Proteomics 3
diﬀerent individuals [45] .A l b u m i ni sap r o t e i no fv e r y
high abundance in serum (35–50mg/mL) that would be a
prime candidate for complete selective removal prior to per-
forming a proteomic analysis of lower abundance proteins.
Thus, removal of albumin from serum may also result in
the speciﬁc removal of low abundance cytokines, peptide
hormones, and lipoproteins of interest. Immunoglobulins,
and antibodies are also abundant proteins in serum that
function by recognizing “foreign” antigens in blood and
initiating their destruction [46]. The presence of higher
abundance proteins interferes with the identiﬁcation and
quantiﬁcation of lower abundance proteins (lower than
ng/mL in serum). Complexity and dynamic range of protein
concentrations can be addressed with a combination of
prefractionation techniques that deplete highly abundant
proteins and fractionate. Heparin chromatography coupled
with protein G appears to be an eﬃcient and economical
strategytopretreatserumforserumproteomics[47].Protein
prefractionation by immunodepletion and reversed-phase
separation of the depleted plasma on mRP-C18 column
provide methods compatible with LC-MS-based analysis. A
polyclonalantibody-basedsystemtorapidlydepletemultiple
high abundant proteins in serum, plasma, CSF, and other
biological ﬂuids. Individual antibody materials are mixed
in selected percentages and packed into a column format.
Albumin can be removed by immunoaﬃnity columns [48],
isoelectric trapping [49], dye-ligand chromatography [50],
andpeptideaﬃnitychromatography[51].Anotherapproach
involves the removal of IgG by aﬃnity chromatography
using immobilized protein A or protein G [52]. A recently
developed depletion method that mixes 6 high-speciﬁcity
polyclonal antibodies (MARS) to remove the top 6 proteins
in a single puriﬁcation step is commercially available [53].
Human-14 multiple aﬃnity removal column depletes the
top 14 abundant proteins from human serum, plasma,
CSF, and other biological ﬂuids. To address 2D limitations
several types of mass spectrometry, in conjunction with
various separation and analysis methods, are increasingly
being adopted for proteomic measurements [54]. In con-
trast, 2D-PAGE analysis, SELDI-TOF MS is a rather new
method which is especially valuable for the identiﬁcation of
serum-derived biomarkers [55]. This method is based on
ProteinChip Arrays which carry various chromatographic
properties, such as anion exchange, cation exchange, and
hydrophilic or hydrophobic surfaces [56]. For the analysis
of serum, only 5–10μL of serum sample is applied to
these surfaces; after washing oﬀ unbound material, the
protein ﬁngerprint can be determined and visualized by
time-of-ﬂight mass spectrometry. The advantages of this
method are the low amount of sample necessary for analysis,
its speed, and high throughput capability. Many diﬀerent
groups have used this method and related methods based on
prefractionation of serum proteins by beads and subsequent
MALDI analysis for the identiﬁcation of biomarkers in
serum, urine, pancreatic juice, and other biological ﬂuids
[57]. The necessity of this removal or separation is also
illustrated that many proteins found useful as biomarkers
[58]. Diﬀerent fractionation steps (such as electrophoresis,
SELDI, and liquid chromatography) have been developed
to reduce the complexity of serum proteome and to allow
the detection and the identiﬁcation of single proteins [59].
2DE and MALDI MS had applied to identify candidate
biomarkers at early and late stages of lung cancer disease.
This method identiﬁed 46 proteins in tumor bearing mice
this included disease regulated expression of orosomucoid-8,
a-2-macroglobulin, apolipoprotein-A1, apolipoprotein-C3,
glutathione peroxidase-3, plasma retinol-binding protein,
and transthyretin [60]. Recently 1065 proteins were iden-
tiﬁed by stable isotope labeled proteome (SILAP) standard
coupled with extensive multidimensional separation with
tandem mass spectrometry of which 121 proteins were
present at 1.5-fold or greater concentrations in the sera of
patients with pancreatic cancer [61]. Specimen collection
(Blood, serum, plasma samples) is an integral component of
clinical research. Access to high-quality specimens, collected
and handled in standardized ways that minimize potential
bias or confounding factors, is key to the “bench to bedside”
aim of translational research [62]. Variables that may impact
analytic outcomes include (1) the type of additive in the
blood collection tubes; (2) sample processing times or tem-
peratures; (3) hemolysis of the sample; (4) sample storage
parameters; (5) the number of freeze-thaw cycles [63, 64].
The key variable in any analysis is that the case and control
samples are handled in the exact same manner throughout
the entire analytical process from study design and collection
ofsamplestodataanalysis[63,65].Thesetypesofdiﬀerences
between samples could have a signiﬁcant impact on the
stability of proteins or other molecules of interest in the
specimens. Small diﬀerences in the processing or handling of
a specimen can have dramatic eﬀects in analytical reliability
and reproducibility, especially when multiplex methods are
used. A representative working group, standard operating
procedures internal working group, comprised of members
from across early detection research network should be
formed to develop standard operating procedures (SOPs)
for various types of specimens collected and managed for
biomarker discovery and validation work.
3.Technologies inProteomics
3.1. Advantages and Technical Limitations of Two-Dimen-
sional Electrophoresis. Figure 1 gives the general work ﬂow
in proteomics and Table 1 addresses their strengths and
limitations. Two-dimensional electrophoresis (2DE) was
developed two decades before the term proteomics was
coined [66, 67]. The 2DE entails the separation of complex
protein mixtures by molecular charge in the ﬁrst dimension
and by mass in the second dimension. 2DE analysis provides
several types of information about the hundreds of proteins
investigated simultaneously, including molecular weight, pI
and quantity, as well as possible posttranslational modiﬁ-
cations. 2DE is extensively used but mostly for qualitative
experimentsandthismethodfallsshortinitsreproducibility,
inability to detect low abundant and hydrophobic proteins,
low sensitivity in identifying proteins with pH values too
low (pH < 3) or too high (pH > 10) and molecular
masses too small (Mr < 10kD) or too large (Mr >
150kD) [2–5]. Poor separations of basic proteins due to4 Human Genomics and Proteomics
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Figure 1: An overview of proteomic strategies.
“streaking” of spots and membrane proteins resolution [68]
are limiting factors in 2DE. However, 2DE is the only tech-
nique that can be routinely applied for parallel quantitative
expression proﬁling of complex protein mixtures such as
w h o l ec e l la n dt i s s u el y s a t e s[ 69]a n dm o s tw i d e l yu s e d
method for eﬃciently separating proteins, their variants and
modiﬁcations (up to 15000 proteins). There are two ways
to study posttranslational modiﬁcations by means of 2DE.
First,posttranslationalmodiﬁcationsthatalterthemolecular
weight and or pI of a protein are reﬂected in a shift in
location of the corresponding protein spot on the proteomic
pattern. Second, in combination with Western blotting,
antibodies speciﬁc for posttranslational modiﬁcations can
reveal spots on 2DE patterns containing proteins with these
modiﬁcations [70]. Protein extraction and solubilization
are key steps for proteomic analysis using 2DE, highly
hydrophobic proteins tend to precipitate during isoelectro
focusing (IEF), low copy number and the insolubility of
transmembrane proteins renders quantitative analysis of
these peptides and polypeptides are very challenging [71].
In order to enhance protein extraction and solubilization,
diﬀerent treatments and conditions are necessary to eﬃ-
ciently solubilise diﬀerent types of protein extracts [72, 73].
The major challenge for protein visualization in 2DE is
the compatibility of sensitive protein staining methods with
mass spectrometric analysis. Therefore, several ﬂuorescent
staining methods have been developed for the visualization
of 2DE patterns, including sypro stainings and Cy-dyes
[74]. Although sypro ruby [75] and silver staining [76, 77]
have a comparable sensitivity, sypro ruby staining allows
much higher reproducibility, a signiﬁcantly wider dynamic
range and less false-positive staining. In addition, sypro
ruby allows for the detection of lipoproteins, glycoproteins,
metalloproteins, calcium-binding proteins, ﬁbrillar proteins,
and low molecular weight proteins that are less “stainable”
using other methods. Finally, a large number of protein spots
on 2DE patterns contain several proteins with a similar pI.
A pH gradient with a narrow range allows zooming into
diﬀerent proteins with the same molecular weight. Increased
separation distance 40 ×40cm gels using CA-IEF [78]c o u l d
increase the proteome coverage up to 5000 proteins. Use of
overlapping narrow range IPGs “Zoom” gels and increase
in separation area could yield better membrane protein
separation [79]. This technology, however, is biased against
certain classes of proteins including low abundance and
hydrophobic proteins.
3.2. Fluorescence 2D Diﬀerence Gel Electrophoresis (2D-
DIGE). Proteins can also be ﬂuorescently labelled with Cy2,
Cy3, or Cy5 prior to 2DE [80]. CyDyes are cyanine dyes
carrying an N-hydroxysuccinimidyl ester reactive group that
covalently binds the e-amino group of lysine residues in
proteins. During DIGE [81], proteins in each of up to 3 sam-
ples can be labelled with one of these ﬂuorescent dyes, and
the diﬀerentially labelled samples can be mixed and loaded
together on one single gel, allowing the quantitative compar-
ative analysis of three samples using a single gel (Figure 2).
The DIGE technique has exhibited higher sensitivity as
well as linearity, eliminated postelectrophoretic processing
(ﬁxing and destaining) steps and enhanced reproducibility
by directly comparing samples under similar electrophoreticHuman Genomics and Proteomics 5
Table 1: Common proteomic technologies, applications, and their limitations.
Technology Application Strengths Limitations
2DE Protein separation Relative quantitative Poor separation of acidic, basis,
hydrophobic and low abundant proteins Quantitative expression proﬁling PTM information
DIGE
Relative quantitative
Protein separation PTM information Proteins without lysine cannot be labeled
Requires special equipment for visualization
and ﬂuorophores are very expensive
Quantitative expression proﬁling High sensitivity
Reduction of intergel variability
ICAT Chemical isotope labeling for
quantitative proteomics
Sensitive and reproducible Proteins without cysteine residues and
acidic proteins are not detected Detect peptides with low
expression levels
SILAC Direct isotope labeling of cells Degree of labelling is very high SILAC labeling of tissue samples is not
possible Diﬀerential expression pattern Quantitation is straightforward
iTRAQ Isobaric tagging of peptides Multiplex several samples Increases sample complexity
Relative quantiﬁcation
High-throughput Require fractionation of peptides before MS
MUDPIT
Identiﬁcation of protein-protein
interactions
High separation Not quantitative
Large protein complexes
identiﬁcation
Diﬃculty in analyzing the huge data set
Deconvolve complex sets of proteins Diﬃcult to identify isoforms
Protein array
Quantitate speciﬁc proteins used in
diagnostics (biomarkers or antibody
detection) and discovery research
High-throughput Limited protein production
Highly sensitive Poor expression methods
Low sample consumption Availability of the antibodies
Accessing very large numbers of aﬃnity
reagents
Mass
spectrometry
Primary tool for protein
identiﬁcation and characterization
High sensitivity and speciﬁcity
High-throughput
Qualitative and quantitative
No individual method to identify all
proteins. Not sensitive enough to identify
minor or weak spots. MALDI and ESI do
not favor identiﬁcation of hydrophobic
peptides and basic peptides
PTM information
Bioinformatics Analysis of qualitative and
quantitative proteomic data
Functional analysis, data mining,
and knowledge discovery from
mass spectrometric data
No integrated pipeline for processing and
analysis of complex data
Search engines do not yield identical results
conditions [81, 82]. The resulting images are then ana-
lyzed by software such as De-Cyder which are speciﬁcally
designed for 2D-DIGE analysis [83]. The major advantages
of 2D-DIGE are the high sensitivity and linearity of its
dyes, its straightforward protocol, as well as its signiﬁcant
reduction of intergel variability, increasing the possibility to
unambiguously identify biological variability, and reducing
bias from experimental variation. Moreover, the use of a
pooled internal standard, loaded together with the control
and experimental samples, increases quantiﬁcation accuracy
and statistical conﬁdence [84]. The DIGE technique has
dramatically improved the reproducibility, sensitivity, and
accuracy of quantitation; however, its labeling chemistry has
some limitations; proteins without lysine cannot be labeled,
and they require special equipment for visualization, and
ﬂuorophores are very expensive [83, 85].
3.3. Isotope-Coded Aﬃnity Tag (ICAT). Gel-free, or MS
based, proteomics techniques are emerging as the meth-
ods of choice for quantitatively comparing proteins levels
among biological proteomes, since they are more sensitive
and reproducible than two-dimensional gel-based methods.
ICAT is one of the most employed chemical isotope labeling
methods and the ﬁrst quantitative proteomic method to
be based solely on using MS [86, 87]. Each ICAT reagent
consists of three essential groups: a thiol-reactive group, an
isotope-coded light or heavy linker, and a biotin segment
to facilitate peptide enrichment. In an ICAT experiment,
protein samples are ﬁrst labeled with either light or heavy
ICAT reagents on cysteine thiols. The mixtures of labeled
proteins are then digested by trypsin and separated through
a multistep chromatographic separation procedure. Peptides
are identiﬁed with tandem MS, and the relative quantiﬁca-
tions of peptides are inferred from the integrated LC peak
areas of the heavy and light versions of the ICAT-labeled
peptides [88]. The ICAT concept has been widely used after
its introduction [89–91]. Diﬀerent software programs were
developed to analyze ICAT labeled MS data (e.g., proICAT
from Applied Biosystems, spectrum Mill from Agilent Tech-
nologies, and Sashimi from the Institute of System Biology
[92]). ICAT is extremely helpful to detect peptides with
low expression levels, which is one of the bottleneck issues6 Human Genomics and Proteomics
(a) (b) (c)
Figure 2:2DE-DIGE subproteome proﬁleof marineorganism,Bryozoan Bugulaneritinaafter IEFfractionation (pI 4.6–5.4) (a)Cy3labeled
swimming larvae, (b) Cy5 labeled settled larvae (c) Cy2 pooled internal standard.
in analytic protein techniques [93, 94]. However, major
limitations of this technique include selective detection of
proteins with high cysteine content and diﬃculties in the
detection of acidic proteins [95, 96]. The methods for direct
comparison of DIGE and ICAT for the identiﬁcation and
quantiﬁcation of proteins in complex biological mixtures are
also being considered [97].
3.4. Stable Isotope Labeling with Amino Acids in Cell Culture
(SILAC). Whilethe ICAT reagentonly interactswiththe free
sulfhydryl of homocysteine and 8% protein is noncysteine,
the SILAC has emerged as a valuable proteomic technique
[98] which becomes more common for cell types and have
been applied in many ﬁelds [99–101]. The SILAC technique
can be eﬀectively expanded to compare the diﬀerential
expression levels of tissue proteome at diﬀerent pathological
states, which allows to identify new candidate biomarkers
[102]. Compared with the ICAT, a popular in vitro labeling,
SILAC as an example of in vivo coding requires no chemical
manipulation, and there is very little chemical diﬀerence
between the isotopically labeled amino acid and its naturally
occurring counterpart [103]. In addition, the amount of
labeled proteins requires for analysis using SILAC technique
is far less than that with ICAT. Therefore, the SILAC-based
method has broadly applied in many areas of cell biology
and proteomics. Except that the SILAC-based quantitative
m e t h o di sp o w e r f u li nc o m p a r a t i v e / d i ﬀerential proteomics,
ithasbeenwidelyusedinanalyzingproteinposttranslational
modiﬁcation, such as protein phosphorylation, detection of
protein-protein or peptide-protein interactions and investi-
gatingsignaltransductionpathways[104,105].Thoughthere
are numerous advantages for using SILAC-based methods
compared to chemical labeling, a major drawback of SILAC
is that it cannot be applied to tissue protein analysis
directly. To overcome this shortcoming, SILAC has been
successfully applied to tissue proteome based on 15Ni s o t o p e
labeling [106]. Microorganisms such as malaria parasite
can be labeled with isoleucine [107]. Latterly the culture-
derived isotope tags (CDITs) method was developed as an
alternative quantitative approach for studying the proteome
of mammalian tissues based on the application of SILAC
[108].
3.5. 18O Stable Isotope Labeling. Diﬀerential 16O/18O cod-
ing relies on the 18O exchange that takes place at the C-
terminal carboxyl group of proteolytic fragments, where
two 16O atoms are typically replaced by two 18O atoms
by enzyme-catalyzed oxygen exchange in the presence of
H218O [109]. The resulting mass shift between diﬀerentially
labeled peptide ions permits identiﬁcation, characterization,
and quantitation of proteins from which the peptides are
proteolytically generated. In contrast to ICAT, 18O labeling
does not favor peptides containing certain amino acids (e.g.,
cysteine), nor does it require an additional aﬃnity step to
enrich for these peptides [110]. Unlike iTRAQ, 16O/18O
labeling does not require a speciﬁc MS platform nor does
it depend on fragmentation spectra (MS2) for quantitative
peptide measurements. It is amenable to the labeling of
human specimens (e.g., plasma, serum, tissues), which
represents a limitation of metabolic labeling approaches
(e.g., SILAC). Taken together, recent advancements in the
homogeneity of 18O incorporation, improvements made on
algorithms employed for calculating 16O/18O ratios and
the inherent simplicity of this technique should result in
increased use of 18O labeling [111]. In general, 18O labeling
suﬀers from two potential drawbacks, inhomogeneous 18O
incorporation and inability to compare multiple samples
within a single experiment. A dual 18O labeling using a
non-gel-based platform has been developed to overcome the
majorproblemsofexistingproteolytic18Olabelingmethods
[112].
3.6. Isobaric Tag for Relative and Absolute Quantitation
(iTRAQ). The iTRAQ reagent is well known for relative and
absolute quantitation of proteins. The iTRAQ technology
oﬀers several advantages, which include the ability to
multiplex several samples, quantiﬁcation, simpliﬁed analysis
and increased analytical precision and accuracy [113–115].
The interest of this multiplexing reagent is that 4 or 8
analysis samples [116] can be quantiﬁed simultaneously.
In this technique, the introduction of stable isotopes
using iTRAQ reagents occurs on the level of proteolytic
peptides (Figure 3). This technology uses an NHS ester
derivative to modify primary amino groups by linking a
mass balance group (carbonyl group) and a reporter groupHuman Genomics and Proteomics 7
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Figure 3: iTRAQ work ﬂow. Adapted from Bill Simon and Toni Slabas, Proteomics Facility, School of Biological and Biomedical Sciences,
University of Durham, UK.
(based on N-methylpiperazine) to proteolytic peptides via
t h ef o r m a t i o no fa na m i d eb o n d[ 117]. Due to the isobaric
mass design of the iTRAQ reagents, diﬀerentially labelled
peptides appear as a single peak in MS scans, reducing
the probability of peak overlapping. When iTRAQ-tagged
peptides are subjected to MS/MS analysis, the mass bal-
ancing carbonyl moiety is released as a neutral fragment,
liberating the isotope-encoded reporter ions which provides
relative quantitative information on proteins. An inherent
drawback of the reported iTRAQ technology is due to the
enzymatic digestion of proteins prior to labelling, which
artiﬁcially increases sample complexity and this approach
needs a powerful multidimensional fractionation method of
peptides before MS identiﬁcation.
3.7. Liquid Phase IEF Fractionation Methods. Prefractiona-
tion of proteins based on electrokinetic methodologies in
free solution essentially relaying on the isoeletric focusing
(IEF) has gained wide acceptance. Many commercial devices
are now constructed to take the advantage of this principle
(Table 2). Reproducible fractionation steps will break down
the sample complexicity while concentrating low abundant
species, resulting in more conﬁdent protein identiﬁca-
tions and quantiﬁcation by 2D gels, mass spectrometry,
and protein arrays. A good example of a innovation is
liquid-phase isoelectric focusing (IEF) as a prefractionation
tool before the ﬁrst dimension of 2D gel electrophoresis
[118, 119]. For more consistent pI separation, the Zoom
IEF fractionator [120] and multicompartment electrolyser
(MCE) [121] are being used to prefractionate the proteins.
The fractionated samples can be directly applied on standard
narrow range IPG strips for 2D electrophoresis. This allows
at least 10000 to 15000 separate proteins to be analyzed,
including proteins of very low abundance. IEF, a high-
resolution electrophoresis technique, has been widely used
in shotgun proteomic experiments [122]. IEF runs in a
buﬀer-free solution containing carrier ampholytes or in
immobilized pH gradient (IPG) gels. The use of IPG-IEF for
the separation of complex peptide mixtures has been applied
to the analysis of plasma and amniotic ﬂuid [123, 124]
as well as to bacterial material [125]. The IPG gel strip is
divided into small sections for extraction and cleaning up
of the peptides. This technique recovers the sample from the
liquid phase and was demonstrated to be of great interest in
shotgun proteomics [126] .I E Fi sn o to n l yah i g hr e s o l u t i o n
and high capacity separation method for peptides, it also
provides additional physicochemical information like their
isoelectric point [127, 128]. The pI v a l u ep r o v i d e di su s e da s
an independent validating and ﬁltering tool during database
search for MS/MS peptide sequence identiﬁcation [129].
The recent introduction of commercially available OFFGEL
fractionator system by Agilent Technologies provides an
eﬃcient and reproducible separation technique [130]. This
separation is based on immobilized pH gradient (IPG) strips
and permits to separate peptides and proteins according to
their isoelectric point (pI) but is realized in solution [131].8 Human Genomics and Proteomics
Table 2: Features of the electrophoretic fractionators most commonly employed for proteomics studies.
Fractionators Applications Strengths Limitation
Rotofor (BioRad) Preparative solution-phase isoelectric
focusing of complex protein mixtures
Retention of the protein’s
biological activity.
No consistent pI cutoﬀ.
Minimum sample loading.
Handle large quantities of
total protein. Overlap between fractions.
Multicompartment
electrolyser
(Proteome systems)
Isolation of low-abundance proteins of
extremely basic or acidic pI.
Precise pI cutoﬀ. Precipitation of proteins.
Higher sample load No consistent protein recovery
Zoom IEF
fractionators
(Invitrogen)
Preparative solution-phase isoelectric
focusing of complex protein mixtures.
Increase the dynamic range
of detection.
Proteins trapped in pH discs.
Cross-contamination of
fractions. Enrich low abundance
proteins. Narrow pI range
3100 OFFGEL
fractionators
(Agilent tech)
Separation of proteins or peptides according
to their isoelectric points.
Peptide isoelectric focusing.
Tedious post-IEF sample
processing
Provides experimental pI
values. Resolution as low as
0.1pH. Fractionation of up
to 16 samples.
Plat form 2D
(Beckman Coulter)
Protein prefractionation based on
chromatofocusing principle.
Flexibility to choose the
number of fractions
acquired per sample.
Low throughput, allowing 2-3
samples per week per
instrument, and large amount
of sample required for analysis High throughput potential
Free ﬂow
electrophoresis
(Becton Dickinson)
Separation of charged analytes like
low-molecular weight organic compounds,
peptides, proteins, protein complexes,
membranes, organelles, and whole cells.
Good sample recovery.
Buﬀers interfere with MS High sample load.
Purify cells or organelles.
Gradiﬂow system
(Gragopore)
2D liquid enrichment system uses
membrane-based electrophoresis to
fractionate protein samples
Good recovery of proteins. Limited sample loading
capacity.
Less-cross contamination Sharp molecular cutoﬀ.
Protein loss
Its micropreparative scale provides fraction volumes large
enough to perform subsequent analyses as reverse phase
(RP)–liquid chromatography (LC)–MALDI MS/MS. The
combined use of iTRAQ labeling and OFFGEL fractionation
methods for the proteomic study of complex sample is also
being considered [132, 133].
3.8. Large-Scale Western Blotting Proteome Analysis. In this
procedure, a large well is used to separate the sample by
PAGE and lanes are created on the membrane containing
immobilized protein with the use of a manifold [134].
Compatible combinations of primary antibodies are prede-
termined, with the criterion of being able to identify proteins
that do not comigrate. Diﬀerent combinations of primary
antibodies are added to each well, with appropriate dilutions
of each primary antibody so that expressed proteins are
detected in a single condition. The scalability of the system
depends on deﬁning suitable combinations of primary
antibodies, with up to 1000 antibodies in 200 lanes being
used in the largest screens. Detection software is used to
identify proteins based on their expected and observed gel
mobility. Unlike 2D PAGE and HPLC-MS/MS, large-scale
westernblotting only identiﬁes proteins forwhich antibodies
are already available. While this is not an appropriate screen
for identifying uncharacterized proteins, it greatly simpliﬁes
the veriﬁcation and functional analyses of proteins that are
detected.Inaddition,thisapproachishighlyﬂexible,andcan
be focused to particular sets of proteins or protein function,
such as cell signaling molecules. Importantly, the foundation
of this approach is the large amount of data on individual
antibodies, which are already available and characterized in
the literature [135].
3.9. Multidimensional Protein Identiﬁcation Technology
(MudPIT). Another approach to analyse proteomes without
gels is “shotgun” analysis using MudPIT [136]. In the
MudPIT approach, protein samples are subject to sequence-
speciﬁc enzymatic digestion, usually with trypsin and
endoproteinase lysC, and the resultant peptide mixtures are
separated by strong cation exchange (SCX) and reversed
phase (RP) high performance liquid chromatography
(HPLC) [137, 138]. Peptides from the RP column enter
the mass spectrometer and MS data is used to search
the protein databases [138]. The MudPIT technique
generates an exhaustive list of proteins present in a
particular protein sample, it is fast and sensitive with good
reproducibility however, it lacks the ability to provide
quantitative information [139–141]. A combination ofHuman Genomics and Proteomics 9
HPLC, liquid phase isoelectric focusing, and capillary
electrophoresis provides other multimodular options for the
separation of complex protein mixtures [142].
4.ProteinMicroarrayTechnology
High throughput production of human proteins using
diﬀerent methods is being developed to make protein
array approach more practical. Recently simple and eﬃcient
production of human proteins using the versatile gateway
vector system has been developed [143]. In this approach,
proteinexpressionsystemisappliedtotheinvitroexpression
of 13364 human proteins and assessed their biological
activity in two functional categories and developed “human
protein factory” infrastructure which includes the resources
and expression technology for in vitro proteome research.
In another approach, DNA array to protein array (DAPA)
is utilized, which allows the “printing” of replicate protein
arrays directly from a DNA array template using cell-
free protein synthesis [144]. Based on the nucleic acid
programmableproteinarray (NAPPA)concept,high-density
self-assembling protein microarray is developed to display
thousands of proteins that are produced and captured in
situ from immobilized cDNA templates [145]. This method
will enable various experimental approaches to study protein
function in high throughput.
The adventage of protein-based microarrays allows the
global observation of biochemical activities on an unprece-
dented scale, where hundreds or thousands of proteins can
be simultaneously screened for protein-protein, protein-
nucleic acid, and protein-small molecule interactions, as well
as posttranslational modiﬁcations [146, 147]. The microar-
ray format provides a robust and convenient platform
for the simultaneous analysis of thousands of individual
protein samples, facilitating the design of sophisticated
and reproducible biochemical experiments under highly
speciﬁc conditions [148]. The principal challenges in protein
array development are 3-fold: (1) creation of a com-
prehensive expression clone library; (2) high-throughput
protein production, including expression, isolation, and
puriﬁcation; (3) adaptation of DNA microarray technology
toaccommodateproteinsubstrates[149].Functionalprotein
microarrays diﬀer from analytical arrays in that functional
protein arrays are composed of arrays containing full-
length functional proteins or protein domains (Figure 4).
These protein chips are used to study the biochemical
activities of an entire proteome in a single experiment.
They are used to study numerous protein interactions, such
as protein-protein, protein-DNA, protein-RNA, protein-
phospholipid, and protein-small molecule interactions [150,
151]. Companies have introduced protein arrays aimed
not only at proteomic analysis but also functional analyses
of proteins (e.g., Biacore AB, Ciphergen Biosystems Inc.,
Phylos Inc.). Aﬃnity proteomics aim to produce antibodies
to every protein expressed by the human genome and
these will be characterized against puriﬁed antigens and
tested on tissue arrays to collect information about their
speciﬁcity for tissue antigens [152]. Companies are focused
to produce various binding partners, for example, aﬃbodies,
monoclonal antibodies, and their fragments [153]. Protein
chips will likely be the next major manifestation of the
revolution in proteomics and oﬀer another solution to
analyze low abundant proteins and have the potential for
high throughput applications to identify biomarkers [154].
Protein chips diﬀer from previously described methods;
whereas screening by 2DE or LC MS/MS can potentially
detect any protein, and protein chips can only provide data
on set of proteins selected by the investigator [155].
4.1. Antibody Microarray. The development and application
of high throughput, multiplex immunoassays that measure
hundreds of known proteins in complex biological matrices,
is becoming a signiﬁcant tool for quantitative proteomics
studies, diagnostic discovery, and biomarker-assisted drug
development. Two broad categories of antibody microarray
experimental formats have been developed [156], direct
labelling, single antibody experiments [157], dual antibody,
sandwich immunoassays are described [158, 159]. In the
direct labelling method, all proteins in a complex mixture
are tagged, providing a means for detecting bound proteins
following incubation on an antibody microarray. In the
sandwich immunoassay format, proteins captured on an
antibody microarray are detected by a cocktail of detection
antibodies, each antibody matched to one of the spotted
antibodies. In addition, a variety of microarray substrates
have been described, including nylon membranes, plastic
microwells, planar glass slides, gel-based arrays and beads in
suspension arrays.
Much eﬀort has been expended in optimizing antibody
attachment to the microarray substrate. Finally, various sig-
nal generation and signal enhancement strategies have been
employedinantibodyarrays,includingcolorimetry,radioac-
tivity, ﬂuorescence, chemiluminescence, quantum dots and
other nanoparticles, enzyme-linked assays, resonance light
scattering, tyramide signal ampliﬁcation, and rolling circle
ampliﬁcation. Each of these formats and procedures has
distinct advantages and disadvantages, relating broadly to
sensitivity, speciﬁcity, dynamic range, multiplexing capa-
bility, precision, throughput, and ease of use. In general,
multiplexed microarray immunoassays are ambient analyte
assays [160]. Given the heterogeneity of antibody array
formats and procedures currently in use in proteomics
studies, and the absence of a “gold standard,” there exists an
urgent need for development and adoption of standards that
permit platform comparisons and benchmarking.
5.MassSpectrometry
Regardless of the choice of a given proteomic separation
technique, gel-based or gel-free, a mass spectrometer is
always the primary tool for protein identiﬁcation. During
the last decade, signiﬁcant improvements have been made
in the application of MS for the determination of protein
sequences[161].Massspectrometersconsistofanionsource,
the mass analyzer, and an ion detection system. Analysis
of proteins by MS occurs in three major steps (a) protein
ionization and generation of gas-phase ions, (b) separation
of ions according to their mass to charge ratio, and (c)10 Human Genomics and Proteomics
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Figure 4: Applications of functional protein microarrays and tissue array.
detection of ions [162]. In gel-free approaches such as ICAT
and MudPIT, samples are directly analyzed by MS whereas,
in gel-based proteomics (2DE and 2D-DIGE), the protein
spots are ﬁrst excised from the gel and then digested with
trypsin. The resulting peptides are then separated by LC
or directly analyzed by MS. The experimentally derived
peptidemassesarecorrelatedwiththepeptideﬁngerprintsof
known proteins in the databases using search engines (e.g.,
Mascot, Sequest). There are two main ionization sources
which include matrix assisted laser desorption/ionization
(MALDI) and electrospray ionization (ESI) and four major
mass analyzers, which are time-of-ﬂight (TOF), ion trap,
quadrupole, and fourier transform ion cyclotron (FTIC)
whicharecurrentlyinuseforproteinidentiﬁcationandchar-
acterization[163].Acombinationofdiﬀerentmassanalyzers
intandemsuchasquadrupole-TOFandquadrupole-iontrap
has combined the individual strengths of diﬀerent types of
mass analyzers and greatly improved their capabilities for
proteome analysis [162]. Simple mass spectrometers such
as MALDI-TOF are used for only measurement of mass,
whereas tandem mass spectrometers are used for amino acid
sequence determination [164]. In MALDI the sample of
interest is crystallized with the matrix on a metal surface
and a laser ion source causes excitation of matrix along
with the analyte ions, which are then released into the
gas phase. MALDI measures the mass of peptides derived
from a trypsinized parent protein and generates a list of
experimental peptide masses, often referred to as “mass
ﬁngerprints” [165, 166]. In ESI, the analyte is ionized from
a solution and transferred into the gas phase by generating
a ﬁne spray from a high voltage needle which results in
multiple charging of the analyte and generation of multiple
consecutive ions. Tandem mass spectrometry or MS/MS is
performed by combining two diﬀerent MS separation prin-
ciples. In tandem MS, individual trypsin-digested peptides
are fragmented after a liquid phase separation. Tandem MS
instruments such as triple quadrupole, quadrupole ion trap,
fourier transform ion-cyclotron resonance, or quadrupole
time-of-ﬂight are used in LC-MS/MS or nanospray experi-
ments with electrospray ionization (ESI) to generate peptide
fragmentionspectra[167].Ionmobilityspectrometry(IMS)
has been utilized as a rapid gas-phase separations strategy
for biomolecular ions [168, 169]. The strategy provides high
sensitivity because the gas-phase dispersion of peptide ions
separates features corresponding to low abundance species
from interfering chemical noise [170]. Reduced spectral
congestionalsoallowsfortheuseofshorterexperimentalrun
times (LC separations) without sacriﬁcing throughput; short
analysis time scales are key to measuring the large numbers
of samples required to determine normal protein variability
prior to realizing individual plasma proﬁling. Additionally,
mobility-dispersed ions can be fragmented and mobility
linkedtofragmentionswithoutionlossfromprecursormass
selection [171] .T h e s ea d v a n t a g e sh a v eb e e nd e m o n s t r a t e d
in head-to-head comparisons with conventional LC-MS/MS
technology using rapid (21minutes) LC gradients [169].
Accuratemassandtime(AMT)tagapproach[172]addresses
an analogous situation in LC-MS-based proteomics studies.
In this approach, initial LC-MS/MS analyses are performed
on prefractionated peptide samples in order to provide
peptide sequence identiﬁcations. These experiments are rela-
tively low throughput because the peptide prefractionation
can be quite extensive and require separate LC–MS/MS
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mass and time (AMT) tag proteomic approach was utilized
to characterize the proteomes for cytoplasm, cytoplasmic
membrane, periplasm, and outer membrane fractions from
aerobic and photosynthetic cultures of the gram-negative
bacterium Rhodobacter sphaeroides 2.4.1. There has been
a recent trend in proteomics toward the development and
application of technologies for the targeted analysis of
proteins within complex mixtures [173]. Selected reaction
monitoring (SRM) is a powerful tandem mass spectrometry
method that can be used to monitor target peptides within
a complex protein digest [174, 175]. The speciﬁcity and
sensitivity of the approach, as well as its capability to
multiplex the measurement of many analytes in parallel, has
made it a technology of particular promise for hypothesis
driven proteomics. The use of tandem mass spectrometry
data acquired on an LTQ ion trap mass spectrometer can
accurately predict which fragment ions will produce the
greatest signal in an SRM assay using a triple quadrupole
mass spectrometer [176]. One of the biggest beneﬁts of a
targeted assay on a triple quadrupole mass spectrometer
is high throughput. Using the selectivity of multiple stages
of mass selection of a tandem mass spectrometer, these
targeted SRM assays are the mass spectrometry equivalent of
aW e s t e r nb l o t[ 173]. An advantage of using targeted mass
spectrometry-based assay over a traditional Western blot is
that it does not rely on the creation of any immunoaﬃnity
reagent. While its application is novel in the proteomics
community, SRM has been utilized for several decades in the
toxicology and pharmacokinetics disciplines [177]. Peptide-
based immunofractionation methods show potential for
proteome wide screening approaches but are limited by
the availability of antibodies [178, 179]. The stable isotope
standards with capture by antipeptide antibodies (SISCAPA)
approach is based on the addition of stable isotope labeled
standard peptides to the digested clinical sample followed by
immunoaﬃnity enrichment of standard and analyte peptide
by highly speciﬁc antipeptide antibodies [180, 181]. This
approach enables the absolute quantiﬁcation of selected
diagnostic peptides from digested clinical samples down to
physiologically relevant analyte concentrations (ng/mL) at
high precision (10% CV) and accuracy [178, 179]. Fur-
ther improvement of MRM-based biomarker quantiﬁcation
should be possible if whole sets of analyte peptides can
be enriched by immunofractionation. Since this method
relies on one speciﬁc antibody per target protein/peptide the
generation of more than 10000 antibodies is necessary for
proteome wide screening approaches. Novel peptide aﬃnity
enrichment strategies enabling proteome wide analyses of
signature peptides may provide an important addition to
future proteome workﬂows. Undoubtedly, the accuracy, high
throughput, and robustness of MS technologies have made
the characterization of entire proteomes a realistic goal [180,
181].
6. Bioinformatics for Proteomics
The major bottlenecks in proteomics research today are
related to data analysis to create an environment where
computerscientistsandbiologistsandthepeoplewhocollect
data can work closely together, so they can develop the
necessary analytical tools that will help interpret the data
[182–184]. Processing and analysis of proteomics data is
indeed a very complex multistep process (Figure 5). The
meaningful comparison, sharing, and exchange of data
or analysis results obtained on diﬀerent platforms or by
diﬀerent laboratories remain cumbersome mainly due to the
lack of standards for data formats, data processing parame-
ters, and data quality assessment. Accurate, consistent, and
transparent data processing and analysis are integral and
critical parts of proteomics workﬂows [185]. We can now
generate huge amounts of data, and currently there is an
enormouschallengetoﬁgureouthowtoactuallyanalyzethis
data and generate real biological insights. The necessity of
an integrated pipeline for processing and analysis of complex
proteomics data sets has therefore become critical.
6.1. Protein Identiﬁcation and Validation. This step consists
of the assignment of MS/MS spectra to a database search
using one of several engines available (e.g., Sequest, Mascot,
Comet, X!tandem, etc.). One of the diﬃculties related to
the use of sequest for peptide identiﬁcations is the lack of
methods to globally evaluate the quality of data and the
lack of methods to access global changes created by ﬁltering
schemes and/or database changes [186]. Most approaches
are matching and scoring large sets of experimental spectra
with predicted masses of fragment ions of peptide sequences
derived fromaprotein database.Resultsarescoredaccording
to a scheme speciﬁc to each search engine that also depends
on the database used for the search. Usually tools are
linked to one speciﬁc platform or were optimized for one
instrument type. The various search engines do not yield
identical results as they are based on diﬀerent algorithms
and scoring functions, making comparison and integration
of results from diﬀerent studies or experiments tedious
[187, 188]. Peptide identiﬁcation via database searches is
very computationally intensive and time-demanding. High
quality data allow more eﬀective searches due to tighter
constrains, that is, tolerance on precursor ion mass and
charge state assignment, which will drastically reduce the
search time in case of an indexed database. In addition,
accurate mass measurements of fragment ions further sim-
plify the database searches and add conﬁdence to the results.
The association of identiﬁed peptides with their precursor
proteins is a very critical and diﬃcult step in shotgun pro-
teomics strategies as many peptides are common to several
proteins, thus leading to ambiguous protein assignments.
Therefore it becomes critical to have an appropriate tool
that is able to assess the validity of the protein inference
and associate a probability to it. Protein Prophet database
tool combines probabilities assigned to peptides identiﬁed
by MS/MS to compute accurate probabilities for the proteins
present [189].
6.2. Data Repositories. Importance of data repositories is
to store, retrieve, and exchange data and results. Typically
proteomics experiments are carried out in isolation by
one single laboratory often in an uncoordinated way, thus
making sharing and comparison of results tedious if not12 Human Genomics and Proteomics
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impossible. The lack of common standards and protocols
has led to this situation and often resulted in duplication of
eﬀorts. Results were usually reported as a set of identiﬁed
proteins (i.e., list of peptides identiﬁed and associated
proteins) with minimal supporting data. Obviously the large
volume of such data sets has made publication of detailed
results using classical mechanisms very challenging. Sharing
and exchange of data and results requires the deﬁnition of
standard formats for the data at all levels (including raw
mass spectrometric data, processed data, and search results)
as well as a better deﬁnition (and/or standardization) of
the parameters used for the data processing or the database
searches.
7. Current Trends in Proteomics
7.1. Organelle Proteomics and Subcellular Fractionation.
Organellar proteomics aims to describe the full complement
of proteins of subcellular structures and organelles. Identi-
ﬁcation of the proteins contained in subcellular organelles
has become a popular proteomics endeavor [190]. When
compared with whole-cell or whole-tissue proteomes, the
more focused results from subcellular proteomic studies
have yielded relatively simpler datasets from which bio-
logically relevant information can be more easily extracted
[191]. Subcellular fractionation consists of two major steps,
disruption of the cellular organization (homogenization)
andfractionationofthehomogenatetoseparatethediﬀerent
populations of organelles. Such a homogenate can then be
resolved by diﬀerential centrifugation into several fractions
containingmainly(1)nuclei,heavymitochondria,cytoskele-
tal networks, and plasma membrane; (2) light mitochondria,
lysosomes, and peroxisomes; (3) golgi apparatus, endosomes
and microsomes, and endoplasmic reticulum; (4) cytosol.
Each population of organelles is characterized by size,
density,charge,andotherpropertiesonwhichtheseparation
relies [192]. Analyzing subcellular fractions and organelles
allows tracking proteins that shuttle between diﬀerent
compartments, for example, between the cytoplasm and
nucleus. A high dynamic range of proteins can be partially
achieved by fractionation of the proteome into subpro-
teomesbyapplyingaﬃnitypuriﬁcationmayallowproteomic
analysis of low copy number proteins [193]. The nuclear,
chloroplast, amyloplast, plasma membrane, peroxisome,
endoplasmic reticulum, cell wall, and mitochondrial pro-
teomes were successfully characterized in Arabidopsis [194].
S e v e r a lg r o u p sh a v et a k e na d v a n t a g eo ft h i sa p p r o a c ht o
recover a higher percentage of membrane proteins from
subcellular extracts using various nonionic and zwitterionic
detergents or phase-partitioning methods. These eﬀorts
resulted in the successful determination of the protein com-
plement of the thylakoid and envelope membrane systems
of the chloroplast [195]. By enriching for the protein class
of interest based on a particular chemical/physical character-
istic(s), oﬀer the advantage of reducing sample complexity
and access to lower abundance proteins in a discovery-
driven experimental approach [196]. Free ﬂow electrophore-
sis (FFE) utilizes diﬀerences in electrophoretic mobility
rather than density to separate cells or subcellular organelles
[197].FFEhaspreviouslybeenusedinseparatingendosomes
from hamster ovary cells [198], plasma membrane from
human platelets [199], and insulin transporting vesicles in
liver cells. The separation is based on the electrophoretic
m o t i l i t yo fc e l l so rc e l lo r g a n e l l e ss u s p e n d e di nav e r t i c a l
free ﬂowing buﬀer ﬁlm on which an electric ﬁeld is
applied at a right angle to the ﬂow direction. FFE has
been a most valuable tool in the investigation of the
composition of secretory vesicles and in addition, it has
clariﬁed how the membrane of plasma membrane vesicles
is oriented after nitrogen disruption of human neutrophils
[200]. Importantly, subcellular fractionation is a ﬂexible
and adjustable approach that may be eﬃciently combined
not only with 2D gel electrophoresis but also with gel-
independent techniques. However, they do have limitations
of considerable cross-contamination with other subcellular
organelles.Human Genomics and Proteomics 13
7.2. Posttranslation Modiﬁcation Analysis (PTM). PTMs of
proteins are considered to be one of the major determinants
regarding organisms complexity [201]. To date, at least more
than 200 diﬀerent types of PTMs have been identiﬁed of
which only a few are reversible and important for the reg-
ulation of biological processes. Speciﬁc functions are usually
mediated through PTMs, such as phosphorylations, acetyla-
tions, or glycosylations, which places additional demands on
the sensitivity and precision of the method [202]. One of the
most studied PTMs is protein phosphorylation, because it is
vital for a large number of protein functions that are impor-
tant to cellular processes spanning from signal transduction,
cell diﬀerentiation, and development to cell cycle control
and metabolism. Enzymes and receptors can be switched
“on” and “oﬀ” by phosphorylation and dephosphorylation.
Itwasestimatedthat10–50%ofproteinsarephosphorylated.
Phosphorylation often occurs on serine, threonine, and
tyrosine residues in eukaryotic proteins [203]. Analysis of
the entire cellular phosphoproteome has been an attractive
study subject since the discovery of phosphorylation as
a key regulatory mechanism of cell life. Unfortunately,
phosphoproteins analysis is not straightforward for ﬁve
main reasons. First, the stoichiometry of phosphorylation
is generally relatively low, because only a small fraction of
the available intracellular pool of a protein is phosphorylated
at any given time as a result of a stimulus. Second, the
phosphorylatation sites on proteins might vary, implying
that any given phosphoprotein is heterogeneous (i.e., it
exists in several diﬀerent phosphorylated forms). Third,
many of the signaling molecules, which are major targets of
phosphorylation events [204], are present at low abundance
within cells and, in these cases; enrichment is a prerequisite
before analysis. Fourth, most analytical techniques used for
studying protein phosphorylation have a limited dynamic
range, which means that although major phosphorylation
sites might be located easily, and minor sites might be diﬃ-
cult to identify. Finally, phosphatases could dephosphorylate
residues unless precautions are taken to inhibit their activity
during preparation and puriﬁcation steps of cell lysates. In
addition, various methods for protein phosphorylation site
determination have been developed, yet this task remains
a technical challenge [205]. Western blot has been widely
used to determine the presence of PTMs. However, this
technique relies on the prior knowledge of the type and
position of speciﬁc modiﬁcations and the availability of
antibodies. It has low throughput and not ideal for studying
highly complicated samples. Speciﬁc chemical or aﬃnity
enrichment steps are usually incorporated into the sample
preparation or fractionation stages of the general scheme
of proteomic studies [206, 207]. Well established methods
involving the analysis of 32P-labeled phosphoproteins by
Edman degradation and two-dimensional phosphopeptide
mapping have proven to be powerful but not without limi-
tations. Consequently, mass spectrometry (MS) has emerged
as a reliable and sensitive method for the characterization
of protein phosphorylation sites [208] and may therefore
represent a method of choice for the analysis of protein
phosphorylation [209]. Immobilized metal aﬃnity chro-
matography (IMAC), Metal oxide aﬃnity chromatography
(MOAC), and covalent methods are all capable of selec-
tively enriching phosphopeptides [210]. MOAC based on
adsorption to TiO2 is especially attractive, but as with all
techniques, loading, rinsing, and elution solutions must be
carefully selected to minimize nonspeciﬁc adsorption and
to maximize the detection of both monophosphorylated
and multiphosphorylated species. IMAC might not provide
the selectivity available with TiO2 enrichment, but with
appropriate reagents, IMAC can be selective and sensitive
for monophosphorylated and tetraphosphorylated peptides.
However, some buﬀers and reagents such as EDTA are
not compatible with IMAC, so HPLC puriﬁcation may
be needed prior to this technique [211]. When trying to
isolate and identify as many phosphoproteins as possible in
a cell lysate, chromatographic column-based methods are
required. Multiple elutions from IMAC or MOAC columns
or even gradient elutions can help to simplify fractions of
proteins and reveal more peptides [212, 213]. A combination
of techniques can reveal large numbers of phosphopeptides
in complex samples, but comprehensive phosphoproteomics
is still not possible. For the highest protein coverage, future
phosphoproteomic techniques will likely employ multiple
enrichment techniques along with two-dimensional separa-
tions, but such studies are time consuming. Combinations of
aﬃnity-based enrichment and extraction methods, multidi-
mensional separation technologies, and mass spectrometry
are particularly attractive for systematic investigation of
posttranslationally modiﬁed proteins in proteomics [214].
7.3. Proteome Analysis of Unsequenced or Nonmodel Organ-
isms. Theapplicationofproteomicsandrelatedtechnologies
for the analysis of proteome is severely hampered by the
lack of publicly available sequence information for most
of the unsequenced organisms [215]. Despite the precision
of the mass information yielded by the SELDI technique,
a signiﬁcant number of proteins were found to have no
similarity to known peptides, an aforementioned weakness
of proteomics studies in nonmodel organisms [216]. In
order to circumvent this limitation, diﬀerent strategies
and tools were developed to make unsequenced organisms
amenable to high-throughput proteomics [217]( Figure 6).
However,anevaluationoftheirperformanceinanintegrated
proteomics strategy using high-throughput shotgun MS data
is currently missing. In principle, two diﬀerent approaches
can lead to an increase in protein identiﬁcations from
unsequenced organisms. In the ﬁrst approach, MS/MS data
are searched against a protein database of an evolutionarily
closely related organism. However, as a matter of principle of
database-dependent searches, only proteins can be identiﬁed
that contain at least one peptide with exactly the same
sequence as the peptide from a protein in the database. With
increasing evolutionary distance this will be an increasingly
severe restriction [218]. In the second approach, the amino
acid sequence of a peptide is extracted from the MS/MS
spectrum for de novo sequencing, that is, in a fully database-
independent manner using exclusively the information con-
tained in the MS/MS spectrum. Several software tools for
peptide de novo sequencing are now available and some
of them provide suﬃciently good results when applied to14 Human Genomics and Proteomics
Confidence hits
De Novo sequences
Homology groupings
Borderline hits
MS/MS spectra
Protein digest Peptide mass map Protein extract
Data base search
Spectra assignment Unassigned high quality spectra
Filtering against back ground library
Remaining spectra De novo sequencing (PepNovo, peaks) 
Reliability filter
MS-Blast
(sequence similarity search)
Peptide identifications Protein identifications
New protein identifications
Retrieved spectra
Figure 6: Workﬂow for protein identiﬁcation in cases where only little sequence information is available for the organism under
investigation.
high-quality spectra [219]. A basic limitation of MS de novo
sequencing methods is the necessity for backbone cleavage
between each pair of adjacent amino acids; a mass value
representing a terminal fragment containing only one of
the two residues is a ﬁrst requirement for ordering of a
speciﬁc pair [220, 221] and this limitation urged the need
for bioinformatics approaches that can help interpret the
proteomics data [219].
8. Closing Remarks
In the past several years there have been very important
extremely useful advances in proteomics methods based
on bottom-up display and bottom-up identiﬁcation using
peptides [222]. These methods oﬀer more sensitivity, greater
rapidity and greater proteome coverage are often made with
the explicit or implicit assertion that these methods are
bound to replace more traditional methods based on top-
down analysis, especially using 2D gels [223, 224]. The
combination of bottom-up display and bottom-up identi-
ﬁcation has achieved very important successes in detecting
the presence of large numbers of diﬀerent proteins in cells
or subcellular organelles [225, 226]. The use of speciﬁc
fractionation schemes and prudent adoption of methods
to increase the number of proteins able to be identiﬁed
and quantiﬁed is enabling signiﬁcant biological advances to
be made. Further technological developments that enable
a larger proportion of the proteome to be visualized will
furtherenhanceourabilitytocharacterizebiologicalsystems.
As such, these advances in proteomics will impact not only
academic pursuits but also pharmaceutical, biotechnology
and diagnostic research and development [227].
In the future gel-free techniques MudPIT, iTRAQ and
18O stable isotope labeling could be expected to gain
more importance as they become more established. Sample
prefractionation system provides a highly valuable tool to
fractionate proteins and peptides from complex eukaryotic
samples like plasma. This approach has a positive inﬂuence
on the number of proteins identiﬁed compared to SCX
method [228]. iTRAQ is a very powerful tool, recognised
form its ability to relatively quantify proteins. iTRAQ
reagent improves MALDI ionisation, especially for peptides
containing lysine. Although SILAC labelling is easy for
any laboratory that uses cell culture, the MS technology
that is required is still beyond the capabilities of most
groups. One of the factors that contributed to the rapid
acceptance of the SILAC technology was the availability of
an open-source program, MSQuant, for interpreting results.
Protein microarrays oﬀer the ability to simultaneously
survey multiple protein markers in an eﬀort to develop
expression proﬁle changes across multiple protein analytes
for potential use in diagnosis, prognosis, and measurement
of therapeutic eﬃcacy [229]. This technology is an excellent
high-throughput method used to probe an entire collection
of proteins for a speciﬁc function or biochemistry. It is
an exceptional new way to discover previously unknown
multifunctional proteins, and to discover new functionalities
for well-studied proteins [230]. A systematic and eﬃcient
analysis of vast genomic and proteomic data sets is a major
challenge for researchers today. To overcome limitations of
current proteomics strategies in regard to the dynamic range
of peptides detected and alternative mass spectrometry-
based approaches are being explored. Targeted strategies
exempliﬁedbymultiplereactionmonitoringdetect,quantify,Human Genomics and Proteomics 15
and possibly collect a product ion spectrum to conﬁrm the
identity of a peptide with much greater sensitivity because
the precursor ion is not detected in the full mass spectrum
[231]. A systematic and eﬃcient evaluation of large-scale
experimental results requires (1) automatic retrieval of user
deﬁned information to construct a customized, queryable
database; (2) an intuitive graphical and query platform to
display and analyze experimental data in the context of
the customized database; (3) eﬃcient utilization of web-
based bioinformatics software tools for data interpretation,
prediction of function, and modeling; (4) scalability and
reconstruction of the database in response to changing
user needs and an ever-expanding base of knowledge and
bioinformatics tools [232]. Creating a software tool to
encompass the four crucial features outlined above is a
challenging and ongoing task, particularly with respect to
the ever-expanding publicly available base of knowledge
and bioinformatics tools. The data processing and analysis
bottleneck can be overcome through integration of the
entire suite of tools into one linear pipeline. The good
news is that all of the various proteomics strategies are in
phases of very rapid technological development and that
importantadvancesinsensitivity,throughput,andproteome
coverage can be expected in the near future for all of
them.
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